Qiagen NV (QGEN) Stock Rating Reaffirmed by Commerzbank AG
QGEN has been the subject of several other reports. DZ Bank AG reaffirmed a buy rating on shares of Qiagen NV in a report on Monday, September 12th. Zacks Investment Research lowered shares of Qiagen NV from a hold rating to a sell rating in a research note on Tuesday, June 21st. Piper Jaffray Cos. reissued a hold rating on shares of Qiagen NV in a research note on Thursday, May 26th. Deutsche Bank AG reissued a buy rating on shares of Qiagen NV in a research note on Monday, June 6th. Finally, Jefferies Group reissued a hold rating on shares of Qiagen NV in a research note on Thursday, August 4th. Seven analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. The company has an average rating of Buy and a consensus price target of $25.36.
Shares of Qiagen NV (NASDAQ:QGEN) opened at 26.45 on Friday. The firm has a market capitalization of $6.19 billion, a price-to-earnings ratio of 52.90 and a beta of 0.90. Qiagen NV has a 52-week low of $19.94 and a 52-week high of $28.04. The stock has a 50 day moving average of $26.75 and a 200 day moving average of $23.37.
Qiagen NV (NASDAQ:QGEN) last posted its quarterly earnings results on Thursday, July 28th. The company reported $0.24 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.23 by $0.01. Qiagen NV had a net margin of 9.13% and a return on equity of 9.21%. The business earned $334.40 million during the quarter, compared to analyst estimates of $326.73 million. During the same period in the previous year, the business posted $0.26 EPS. The company’s quarterly revenue was up 4.7% on a year-over-year basis. On average, analysts predict that Qiagen NV will post $1.09 EPS for the current fiscal year.
Large investors have recently added to or reduced their stakes in the stock. Fuller & Thaler Asset Management Inc. purchased a new stake in Qiagen NV during the second quarter worth about $116,000. First Mercantile Trust Co. purchased a new stake in Qiagen NV during the second quarter worth about $126,000. Societe Generale purchased a new stake in Qiagen NV during the second quarter worth about $152,000. SG Americas Securities LLC raised its stake in Qiagen NV by 9.9% in the second quarter. SG Americas Securities LLC now owns 6,977 shares of the company’s stock worth $152,000 after buying an additional 629 shares in the last quarter. Finally, Royal Bank of Canada raised its stake in Qiagen NV by 25.2% in the first quarter. Royal Bank of Canada now owns 7,712 shares of the company’s stock worth $173,000 after buying an additional 1,553 shares in the last quarter. Institutional investors and hedge funds own 58.76% of the company’s stock.
Qiagen NV Company Profile
QIAGEN N.V. (QIAGEN) is a holding company. The Company and its subsidiaries are engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Sample to Insight solutions are composed of sample and assay technologies, bioinformatics and automation systems.
Receive News & Ratings for Qiagen NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen NV and related companies with MarketBeat.com's FREE daily email newsletter.